I met with aluminum
نویسندگان
چکیده
منابع مشابه
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
We sought to investigate the demographics and tumor-associated features in patients with gastroesophageal (GE) malignancies referred to our Phase I Program who had formalin-fixed, paraffin-embedded tissue from archival or new biopsies tested for MET mutation and/or amplification. MET amplification was found in 5 of 76 (6.6%) patients (3/34 [8.8%] esophageal, 2/26 [7.7%] gastric and none in 22 g...
متن کاملMetamorphosis starts with Met.
J uvenile hormone (JH) has long been known to be a potent regulator of metamorphosis in most insects, but learning how it acts has been hindered until now by failure to find an entry point for its mechanism of action. Using the beetle Tribolium castaneum, Konopova and Jindra (1) have achieved a result long and fruitlessly sought in Drosophila, which is reported in this issue of PNAS. They have ...
متن کاملAluminum Tolerance in Wheat (Triticum aestivum L.) (I. Uptake and Distribution of Aluminum in Root Apices).
We investigated the uptake and distribution of Al in root apices of near-isogenic wheat (Triticum aestivum L.) lines differing in Al tolerance at a single locus (Alt1: aluminum tolerance). Seedlings were grown in nutrient solution that contained 100 [mu]M Al, and the roots were subsequently stained with hematoxylin, a compound that binds Al in vitro to form a colored complex. Root apices of Al-...
متن کاملThe Release of Aluminum from Aluminosilicate Minerals. I. Kinetics
-The rates of release of AI by M NH~NO3 (pH 3) from minerals saturated with AI ions at pH 3 suggest that AI ions migrated from the surface layers and the matrix cores of kaolinite, montmorillonite, illite, and biotite, but only from the matrix core of muscovite mica. From the 0.25-0.5 p.m kaolinite and montmorillonite, part of the 'surface' A1 is released 'instantaneously' and the rest by first...
متن کاملPhase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and MET amplification (NCT01657214). SAR125844 was administered by intravenous infusion (260-570 mg/m2) on days 1, 8, 15, and 22 of each 28-day c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Japan Institute of Light Metals
سال: 1981
ISSN: 0451-5994
DOI: 10.2464/jilm.31.697